Kosice

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 Immune system diseases
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending
  2025-523425-17-00 4 Proteinuric kidney diseases
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-524040-35-00 5 Severe uncontrolled asthma
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 Crohn’s Disease
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting
  2025-524265-24-00 5 2026-05-21 Dyslipidemia at High to Very High Cardiovascular Risk
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo … Recruiting
  2025-522093-36-00 10 2026-05-20 Cancer cachexia
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2 … Recruiting
  2025-521936-12-00 5 2026-04-24 Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting
  2025-520721-21-00 4 2025-10-20 Rheumatoid Arthritis
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520195-94-00 5 2025-09-25 BP-I mania or mania with mixed features
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 5 2025-09-25 Mania or Mania with Mixed Features in Bipolar-I Disorder

Showing 1–24 of 184 trials